文献速递肿瘤 PET/CT

[18F]FMISO PET/CT 作为胰腺癌患者术前预后因素

[18F]FMISO PET/CT as a preoperative prognostic factor in patients with pancreatic cancer.
PubMed 文献 · EJNMMI Res · 2019-05-09

本研究纳入25例初诊拟手术的胰腺腺癌患者,术前接受[18F]FMISO PET/CT,以肿瘤SUVpeak除以主动脉SUVpeak计算TBRpeak,评估其与HIF-1α表达、可手术性及生存的关系。结果显示TBRpeak高组无复发生存和总生存均显著更短,提示[18F]FMISO PET/CT可能作为术前预后因素。

要点

  • 25例胰腺腺癌患者中9例(36.0%)[18F]FMISO PET/CT视觉阳性。
  • TBRpeak cutoff为1.24,高TBRpeak组无复发生存显著更短(中位218 vs 441天,p=0.002)。
  • 可手术患者中高TBRpeak组总生存显著更短(中位415 vs >1000天,p=0.04)。

核心结论

  • [18F]FMISO PET/CT有可能作为胰腺癌患者的术前预后因素。

研究设计与样本

  • 纳入25例初诊拟手术的胰腺腺癌患者(11女14男,中位年龄73岁,范围58-81岁),术前接受[18F]FMISO PET/CT。
  • 以肿瘤SUVpeak除以主动脉SUVpeak计算TBRpeak,并与HIF-1α免疫组化及生存进行对比分析。
  • 观察时间39-1101天(中位369天),采用Kaplan-Meier法评估复发无生存和总生存。

主要发现

  • 9例(36.0%)在[18F]FMISO PET/CT图像上视觉阳性。
  • 视觉阴性病例TBRpeak显著低于阳性病例(中位1.08,IQR 1.02-1.15 vs 中位1.50,IQR 1.25-1.73,p<0.001)。
  • 可手术与不可手术患者TBRpeak无显著差异(中位1.48,IQR 1.06-1.98 vs 中位1.12,IQR 1.05-1.21,p=0.10)。
  • TBRpeak与HIF-1α表达无显著差异(p=0.22)。
  • 按TBRpeak cutoff分组,高组无复发生存显著更短(中位218 vs 441天,p=0.002)。

关键数值与推荐

  • TBRpeak cutoff计算为1.24。
  • 视觉阳性9例(36.0%)。

临床怎么用

  • 术前[18F]FMISO PET/CT的TBRpeak可能帮助识别胰腺癌预后较差的患者。
  • 高TBRpeak(>1.24)提示无复发生存和总生存更短,或可辅助术前风险分层。

局限性

  • 样本量小(25例),观察时间范围宽(39-1101天)。
  • TBRpeak与HIF-1α表达无显著相关(p=0.22)。
  • 可手术与不可手术患者TBRpeak无显著差异(p=0.10)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: While [18F]fluoromisonidazole (FMISO), a representative PET tracer to detect hypoxia, is reported to be able to prospect the prognosis after treatment for various types of cancers, the relation is unclear for pancreatic cancer. The aim of this study is to assess the feasibility of [18F]FMISO PET/CT as a preoperative prognostic factor in patients with pancreatic cancer. METHODS: Patients with pancreatic cancer who had been initially planned for surgery received [18F]FMISO PET/CT. Peak standardized uptake value (SUV) of the pancreatic tumor was divided by SUVpeak of the aorta, and tumor blood ratio using SUVpeak (TBRpeak) was calculated. After preoperative examination, surgeons finally decided the operability of the patients. TBRpeak was compared with hypoxia-inducible factor (HIF)-1α immunohistochemistry when the tissues were available. Furthermore, correlation of TBRpeak with the recurrence-free survival and the overall survival were evaluated by Kaplan-Meyer methods. RESULTS: We analyzed 25 patients with pancreatic adenocarcinoma (11 women and 14 men, median age, 73 years; range, 58-81 years), and observed for 39-1101 days (median, 369 days). Nine cases (36.0%) were identified as visually positive of pancreatic cancer on [18F]FMISO PET/CT images. TBRpeak of the negative cases was significantly lower than that of the positive cases (median 1.08, interquartile range (IQR) 1.02-1.15 vs median 1.50, IQR 1.25-1.73, p < 0.001), and the cutoff TBRpeak was calculated as 1.24. Five patients were finally considered inoperable. There was no significant difference in TBRpeak of inoperable and operable patients (median 1.48, IQR 1.06-1.98 vs median 1.12, IQR 1.05-1.21, p = 0.10). There was no significant difference between TBRpeak and HIF-1α expression (p = 0.22). The patients were dichotomized by the TBRpeak cutoff, and the higher group showed significantly shorter recurrence-free survival than the other (median 218 vs 441 days, p = 0.002). As for overall survival of 20 cases of operated patients, the higher TBRpeak group showed significantly shorter overall survival than the other (median survival, 415 vs > 1000 days, p = 0.04). CONCLUSIONS: [18F]FMISO PET/CT has the possibility to be a preoperative prognostic factor in patients with pancreatic cancer.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Yamane T, Aikawa M, Yasuda M, et al. [18F]FMISO PET/CT as a preoperative prognostic factor in patients with pancreatic cancer. EJNMMI Res. 2019. PMID: 31073705. doi:10.1186/s13550-019-0507-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。